|
|
|
USHERCELL'S NOVEL CLINICAL TRIAL DESIGN
FACES RECRUITMENT CHALLENGES
CONTRACEPTIVE DEVELOPMENT TIMELINE NOT AFFECTED |
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS LIMITED -
THIRD QUARTER RESULTS |
| |
|
|
|
|
|
PHASE III USHERCELL (CELLULOSE SULFATE)
TRIAL
FOR HIV PREVENTION UNDER WAY |
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS REPORTS SECOND
QUARTER RESULTS |
| |
|
|
|
|
|
POLYDEX REPORTS FIRST QUARTER PROFIT
OF $1,260,668 |
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS LIMITED -
2004 FISCAL YEAR END RESULTS |
| |
|
|
|
|
|
POLYDEX
ANNOUNCES THAT CONRAD
HAS INITIATED CONTRACEPTIVE CLINICAL TRIALS OF USHERCELL WITH
FUNDING FROM THE BILL AND MELINDA GATES FOUNDATION
ADDITIONAL INTERNATIONAL TRIAL PREPARATIONS
UNDERWAY TO ASCERTAIN EFFECTIVENESS OF USHERCELL AS A TREATMENT
OF BACTERIAL VAGINOSIS
|
| |
|
|
|
|
|
POLYDEX
COMPLETES SALE OF U.S. FACILITY
$5.5 MILLION IN CASH TO ADVANCE
USHERCELL RESEARCH AND PLANT UPGRADES
|
| |
|
|
|
|
|
POLYDEX'S USHERCELL COMPLETES FURTHER
PHASE I TRIALS PROCEEDS TO PHASE II CONTRACEPTIVE TRIALS |
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS SELLS
UNITED STATES VETERINARY PHARMACEUTICAL BUSINESS
WILL FOCUS ON DEVELOPMENT OF HUMAN PHARMACEUTICAL PRODUCTS
|
| |
|
|
| |
|
|
